Glowwiki
KR
CN
JP
Tag
metastatic pancreatic adenocarcinoma treatment
— 1 page
Closed
FDA Approves Daraxonrasib (Rasonque) — First RAS-Targeted Therapy for Metastatic Pancreatic Cancer
On Aug 26, 2026 the FDA approved Rasonque (daraxonrasib), Revolution Medicines' first-in-class RAS inhibitor for metastatic pancreatic cancer; trial survival was 13.2 vs 6.7 months.
Science · Aug 27
← All pages